Skip to main content
OTCMKTS:GNFTF

Genfit Stock Forecast, Price & News

$4.17
0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.17
▼
$4.17
50-Day Range
$4.17
▼
$4.87
52-Week Range
$3.75
▼
$21.30
VolumeN/A
Average Volume396 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GNFTF News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.


Genfit logo

About Genfit

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

Headlines

GENFIT Provides Pipeline Update and Launch of New Clinical Programs
GENFIT Provides Pipeline Update and Launch of New Clinical Programs
May 11, 2021 |  finance.yahoo.com
GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents
GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents
May 10, 2021 |  finance.yahoo.com
GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT’s NIS4™ Technology to Identify Patients with At-Risk NASH
GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT’s NIS4™ Technology to Identify Patients with At-Risk NASH
May 3, 2021 |  finance.yahoo.com
Genfit SA (OTCMKTS:GNFTF) Sees Significant Growth in Short Interest
Genfit SA (OTCMKTS:GNFTF) Sees Significant Growth in Short Interest
April 29, 2021 |  americanbankingnews.com
GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee
GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee
April 22, 2021 |  finance.yahoo.com
GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update
GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update
April 1, 2021 |  finance.yahoo.com
GENFIT: 2021 Financial Calendar
GENFIT: 2021 Financial Calendar
February 13, 2021 |  markets.businessinsider.com
GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology
GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology
February 9, 2021 |  finance.yahoo.com
GENFIT: New Data Presented at AASLD The Liver Meeting Digital Experience™
GENFIT: New Data Presented at AASLD The Liver Meeting Digital Experience™
November 16, 2020 |  finance.yahoo.com
GNFTF Real-Time Quotes
GNFTF Real-Time Quotes
October 27, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNFTF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.genfit.com
Phone33 3 20 16 40 00
Employees203
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.46 out of 5 stars

Medical Sector

1680th out of 2,044 stocks

Biotechnology Industry

109th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Genfit (OTCMKTS:GNFTF) Frequently Asked Questions

What stocks does MarketBeat like better than Genfit?

Wall Street analysts have given Genfit a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genfit wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Genfit?

Genfit saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,100 shares, an increase of 120.0% from the March 31st total of 500 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is presently 5.5 days.
View Genfit's Short Interest.

How has Genfit's stock price been impacted by Coronavirus?

Genfit's stock was trading at $14.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNFTF shares have decreased by 70.4% and is now trading at $4.17.
View which stocks have been most impacted by COVID-19.

Who are Genfit's key executives?

Genfit's management team includes the following people:
  • Mr. Jean-François Mouney, Co-Founder & Chairman (Age 66, Pay $1.64M)
  • Mr. M. Pascal Prigent, Chief Exec. Officer (Age 53, Pay $382.61k)
  • Prof. Bart Staels, Co-Founder & Chairman of the Scientific Advisory Board (Age 58)
  • Ms. Nathalie Huitorel, Exec. VP and Chief Financial & Admin. Officer (Age 60)
  • Dr. Dean W. Hum, Chief Operating Officer (Age 59)
  • Ms. Naomi Eichenbaum, VP of Investor Relations
  • Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 51)
  • Mr. Jean-Christophe Marcoux, Chief Strategy Officer (Age 44)
  • Dr. Carol L. Addy M.D., Chief Medical Officer (Age 61)
  • Mr. Suneil Hosmane Ph.D., Head of Global Diagnostics (Age 39)

Who are some of Genfit's key competitors?

Some companies that are related to Genfit include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of GNFTF's competitors.

What is Genfit's stock symbol?

Genfit trades on the OTCMKTS under the ticker symbol "GNFTF."

How do I buy shares of Genfit?

Shares of GNFTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genfit's stock price today?

One share of GNFTF stock can currently be purchased for approximately $4.17.

How many employees does Genfit have?

Genfit employs 203 workers across the globe.

What is Genfit's official website?

The official website for Genfit is www.genfit.com.

How can I contact Genfit?

The company can be reached via phone at 33 3 20 16 40 00.


This page was last updated on 5/15/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.